Shanghai Pharma Plans To Sell 13.73 Percent Stake In Kangtai Biotech
This article was originally published in PharmAsia News
Shanghai Pharma plans to sell its 13.73 percent stake in Kangtai Biotech at RMB 1.7 per share, for a total of RMB 83.3 million
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.